0000000000038278
AUTHOR
Clementina Savastano
showing 2 related works from this author
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a r…
2018
Background: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. Methods: FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely remov…
A new case of radiation-induced breast angiosarcoma
2019
Highlights • A biopsy of any suspicious breast skin lesion after radiotherapy is recommended. • Patients with clinical anomalies post-breast cancer surgery and RT need attention. • The Angiosarcoma was cured due to surgery and high-dose neoadjuvant chemotherapy. • A correct 6 month follow-up is needed: check-ups, chest X-rays and ultrasound. • The survival of the patient suggests possible ways to manage this rare tumour type.